Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Country
Sector
Themes
Also in
Price· split & dividend adjusted
No price history for this asset yet.
News & notes movingDHR
DHR▲
Danaher Biotechnology Segment Sales Rise 4% in Q2
Danaher Corporation's Biotechnology segment reported second-quarter 2026 sales of $1.92 billion, up 4% year over year, with core revenues increasing 2.5%. The growth was driven by stronger demand in China, higher consumables and equipment sales in bioprocessing, and improved discovery and medical business. However, difficult prior-year comparisons in Western Europe and North America and shipment timing shifts by large customers remain concerns. Danaher expects the segment's core revenues to grow in the mid-single digits in 2026. Shares of Danaher have gained 24.4% in the past month, and the company carries a Zacks Rank #3 (Hold).
Masimo Receives FDA Clearance for Continuous Oxygen Delivery Monitoring
Masimo, a Danaher company, announced FDA 510(k) clearance for its Root with LiDCO hemodynamic monitoring solution, including the Masimo LiDCO sensor, enabling continuous monitoring of oxygen delivery. The system combines continuous noninvasive hemoglobin, Masimo SET oxygen saturation, and cardiac output to provide a beat-to-beat view of oxygen being delivered to tissue. Dr. Basil Matta, Chief Medical Officer at Masimo, said the technology gives clinicians a continuous view of oxygen delivery and helps them better understand changes in a patient's oxygen supply as they occur. Clinical studies cited by the company showed preoperative optimization of oxygen delivery reduced mortality from 17% to 3% in one trial, and another trial demonstrated a 75% reduction in 28-day mortality when targeting oxygen delivery greater than 600 mL/min/m².
Merck and Moderna Cancer Vaccine Success Lifts Five Biotech Stocks
Merck and Moderna announced positive topline Phase 3 results for their individualized cancer vaccine intismeran autogene in resected melanoma, beating Keytruda alone on recurrence-free survival, though no specific efficacy numbers have been released yet. The news lifted several biotech names, with BioNTech surging 21.6% on read-across excitement and Illumina rising 15.6% to $223.22 because its NovaSeq X sequencers are required for every individualized neoantigen dose manufactured. Pacific Biosciences gained 5.8% to $1.28, Repligen traded at $181.62 after reporting second-quarter revenue of $204 million with 13% organic growth, and Danaher saw mid-teens bioprocessing order growth in the second quarter. Leerink Partners analyst Daina Graybosch called the market reaction overly optimistic but still raised her 2032 intismeran forecast to $1.4 billion, while Morningstar projects $16.8 billion by 2035.
Abbott Diagnostics Growth Shifts to Cancer Testing
Abbott Laboratories' Diagnostics business is increasingly relying on its Cancer Diagnostics arm as respiratory testing volumes remain weak. In the second quarter of 2026, Rapid and Molecular Diagnostics sales fell 8% on a comparable basis due to a weaker-than-normal respiratory season, while Cancer Diagnostics sales grew 13%, driven by mid-teens growth in Cologuard. Peer QuidelOrtho reported respiratory products accounted for 9% of total revenues in the first half of 2026, down from 13% a year earlier, and Danaher's Diagnostics segment core revenues declined 4% in the first quarter of 2026. Abbott shares have fallen 11.6% over the past year, and the stock trades at a forward 12-month price-to-sales ratio of 3.81 times versus the industry median of 2.81 times.
Danaher and Medtronic Recoveries Diverge on Drivers
Danaher and Medtronic are both showing signs of recovery, but their paths differ sharply. Medtronic reported its highest annual revenue growth in 10 years in fiscal Q4 and full-year 2026, with Q4 revenue reaching $9.8 billion, up 9.9% as reported and 6.6% organic, and full-year revenue of $36.4 billion, up 8.4% as reported and 5.8% organic. Danaher, meanwhile, cut the upper end of its full-year core revenue growth outlook to 4% from 6%, while maintaining the lower end at 3%, citing weaker respiratory testing revenue. Hedge fund ownership declined for both stocks between Q4 2025 and Q1 2026, with Danaher falling from 125 funds to 110 and Medtronic from 63 to 60.
Danaher Bioprocessing Miss Weighs on Bio-Rad Shares
Danaher Corporation's second-quarter bioprocessing unit miss sent ripples across the life sciences sector, pressuring Bio-Rad Laboratories shares in early New York trading. Danaher reported Q2 2026 revenue of $6.3 billion, up 5.5% year-over-year, with adjusted diluted EPS rising 8% to $1.94 and free cash flow of $1.3 billion, and raised its full-year adjusted EPS guidance to $8.45–$8.60. Bio-Rad posted Q2 net sales of $651 million, essentially flat, with its Life Science segment down 4.1% to $252 million, and announced a restructuring plan on July 31, 2026 involving global headcount reductions and facility closures expected to generate $80 million to $90 million in pre-tax charges. RBC Capital subsequently raised its price target on Bio-Rad to $370 from $320, maintaining an Outperform rating, while Danaher named Julie Sawyer Montgomery as CEO. Hedge fund data showed institutional investors trimmed positions in both stocks during Q1 2026, with Bio-Rad held by 35 hedge funds and Danaher by 110.
Thermo Fisher Outpaces Danaher in Life Sciences Recovery as Q2 Results Diverge
Thermo Fisher Scientific and Danaher reported diverging second-quarter results, with Thermo Fisher raising its full-year guidance while Danaher lowered the upper end of its core revenue growth outlook. Thermo Fisher's revenue grew 10% to $11.99 billion, with adjusted EPS up 13% to $6.03, driven by broad-based demand improvement across pharmaceutical and biotech markets. Danaher's core growth improved sequentially but was marked by uneven recovery, including a $100 million revenue shift into next year due to customer project timing. Hedge fund ownership of Thermo Fisher rose to 115 funds in the first quarter of 2026 from 113 in the prior quarter, while Danaher's fell from 125 to 110 funds over the same period.
Danaher DCF suggests 15% upside but P/E still flags overvaluation after CEO change
Danaher shares trade around $194.78 after a weak earnings update and the planned 2026 CEO transition to Julie Sawyer Montgomery, with a Discounted Cash Flow analysis pointing to an intrinsic value of about $230 per share, implying a roughly 15.2% discount. The DCF model starts with trailing twelve-month free cash flow of approximately $5.3 billion and assumes continued growth from that base. However, Danaher’s price-to-earnings ratio of about 34.3 times sits above a tailored fair P/E of roughly 28.9 times, signaling overvaluation on earnings even though it is below the Life Sciences industry average of around 37.6 times and the peer group average of about 79.6 times. Broader checks score 3 out of 6, reflecting a mixed picture as investors weigh whether execution under the new CEO and future cash flow delivery can justify the current earnings multiple or confirm a value trap.
Abbott beats Q2 estimates and raises profit outlook while Danaher cuts revenue guidance
Abbott Laboratories beat fiscal second-quarter 2026 estimates and raised its full-year adjusted earnings guidance, while Danaher Corporation cut its core revenue growth outlook following mixed quarterly results. Abbott reported adjusted diluted EPS of $1.31, with diagnostics sales surging 42% to $3.09 billion, and lifted its 2026 adjusted EPS forecast to a range of $5.45 to $5.60. Danaher posted a 5.5% revenue increase to $6.3 billion and adjusted EPS of $1.94 that exceeded analyst estimates, but lowered the upper end of its full-year core revenue growth outlook to 4% from 6%, citing weaker respiratory testing revenue. Hedge fund ownership of Abbott rose to 73 in the first quarter of 2026, while Danaher's fell to 110, reflecting diverging institutional sentiment.
Danaher beats Q2 earnings estimates but cuts full-year core revenue growth outlook
Danaher Corporation delivered second-quarter results that beat earnings estimates, yet investors remain concerned after the company cut its full-year core revenue growth outlook and reported weaker-than-expected bioprocessing revenue. Non-GAAP adjusted earnings per share reached $1.94, above the $1.83 consensus, while revenue grew 5.5% year-over-year to $6.3 billion. However, the company lowered the upper end of its 2026 core revenue growth forecast to 4% from 6%, citing weaker respiratory testing revenue, and disclosed that over $100 million in bioprocessing revenue shifted into next year. BofA maintained a Buy rating but cut its price target to $230 from $270, noting the results were messier than expected and the stock fell 11%. Danaher raised its full-year adjusted EPS guidance to a range of $8.45 to $8.60, reflecting optimism from strong quarterly performance and the early completion of the Masimo acquisition.
Agilent Technologies Gains EU Approval for Ovarian Cancer Companion Diagnostic
Agilent Technologies has received European certification for its PD-L1 IHC 22C3 pharmDx test as a companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma, enabling pathologists to identify patients who may benefit from Merck's Keytruda. This marks the eighth CE-marked indication for the 22C3 assay in the EU, following an FDA approval of a related PD-L1 test for esophageal and gastric cancers nine days earlier. The approval extends the reach of an existing assay already used in labs worldwide, supporting Agilent's strategy of compounding its diagnostics footprint through incremental label expansions rather than relying on a single blockbuster product. The company also recently closed its acquisition of Biocare Medical to deepen its clinical pathology presence. However, Agilent faces competition from Danaher's Leica Biosystems, which is strengthening its own pathology pipeline with the planned acquisition of StatLab Medical Products, and the broader life sciences tools sector remains sensitive to growth outlook revisions, as seen when Danaher's stock fell 14% after trimming its core revenue growth forecast.
Danaher Appoints Julie Sawyer Montgomery as President and CEO
Danaher Corporation has appointed Julie Sawyer Montgomery as President and Chief Executive Officer, effective October 1, 2026. She succeeds Rainer Blair, who will retire and serve as a senior advisor until March 31, 2027 to ensure a seamless transition. Ms. Sawyer Montgomery joined Danaher in 2017 and helped grow the Diagnostics platform from approximately $6.0 billion in revenue to approximately $11.0 billion today, while approximately tripling operating profit. She most recently served as Executive Vice President with responsibility for the Diagnostics platform. The company also announced special equity incentive awards for key leadership members and founders, and stated there is no change to its previously communicated third quarter and full-year 2026 guidance.
Johnson & Johnson raises outlook as pharma offsets Stelara decline, while Danaher cuts guidance after messy quarter
Johnson & Johnson raised its full-year guidance after second-quarter sales grew nearly 7% to $25.31 billion, beating the $25.05 billion estimate, while Danaher cut the upper end of its core revenue growth outlook range to 4% from 6% following a quarter that BofA called messier than expected. Johnson & Johnson's pharmaceutical unit generated $16.38 billion in quarterly sales, exceeding the $16.1 billion estimate, as a 72.5% surge in Tremfya sales to $2 billion helped offset a more than 55% drop in Stelara revenue to $740 million due to patent loss. The company now expects annual sales of about $101.1 billion at the midpoint and raised its adjusted earnings per share forecast to $11.68 from $11.55. Danaher's Life Sciences business delivered its strongest performance in several years, with bioprocessing orders growing mid-teens, but weaker-than-expected biotechnology revenue and a shift of a little over $100 million in revenue into next year weighed on results. Hedge fund ownership of Johnson & Johnson rose to 113 in the first quarter of 2026 from 104 in the prior quarter, while Danaher's fell to 110 from 125, according to Insider Monkey data.
AMR Diagnostics Becomes an Investment Fortress Against the Superbug Crisis
The crisis of antimicrobial resistance, or superbugs, is driving investment into the AMR Diagnostics sector, which serves as the diagnostic and containment infrastructure for drug-resistant infections. By 2050, superbugs could claim more lives than cancer if adequate systems are not in place. Danaher Corporation, through its subsidiary Cepheid, leads in molecular diagnostic radar systems with the GeneXpert instrument, generating recurring revenue from test cartridges. Meanwhile, Becton, Dickinson and Company dominates the automated microbiology lab market with a consumables sales model that carries very high switching costs. Investment in this sector is thus seen as a defensive theme with predictable cash flows and strong demand from public health systems worldwide.
Danaher Could Be 16% Undervalued Based on Earnings and 2026 Revenue Guidance
Danaher shares may be undervalued by about 16% relative to a fair value estimate of $228.61, according to a Simply Wall St analysis, even after the stock fell 16.9% year to date. The company recently issued third quarter 2026 revenue guidance of 2% to 3% growth and detailed share repurchases alongside its latest quarterly earnings. The fair value estimate assumes mid-single-digit revenue expansion, faster earnings growth, and a richer margin mix driven by life sciences and diagnostics, including AI-assisted diagnostic solutions and support for in vivo CRISPR therapies. However, the narrative also depends on bioprocessing recovery and China, where policy shifts and lumpy consumables demand could unsettle those assumptions.
Danaher Stock Slump This Week Looks Like a Buying Opportunity
Danaher shares fell 12.1% this week despite second-quarter earnings beating estimates and management raising full-year EPS guidance to $8.45-$8.60 from $8.35-$8.55. The decline was driven by a reduction in full-year core sales growth expectations for the high-margin biotechnology segment, where consumables sales missed expectations due to a few large chromatography resin shipments moving out of the year. Analysts questioned why the shipments would not simply shift to later quarters, and CEO Rainer Blair confirmed the timing change. The sell-off appears to be an overreaction to an otherwise positive report, presenting a potential buying opportunity for long-term investors.
Apple Fails to Overturn $634 Million Masimo Verdict
Apple failed to overturn a $634 million jury verdict in a patent dispute with medical technology company Masimo. A federal judge in California rejected Apple's request to set aside the award, which centered on blood oxygen measurement technology in certain Apple Watch models. The court also found that Apple misappropriated two of 14 Masimo trade secrets but declined to issue an injunction and ruled that Masimo could not seek monetary damages on that part of the case. Masimo, now part of Danaher, had sought as much as $3.1 billion tied to the trade-secret claims and has filed an appeal over that portion of the ruling. Apple has argued that its engineers developed the health-monitoring features independently.
S&P 500 Futures Rise as Investors Weigh Inflation and Earnings
US stock futures pointed higher with S&P 500 contracts up about 0.5% and Nasdaq 100 futures up roughly 1.3% as investors balanced fresh inflation worries against easing rate fears abroad. The 10-year Treasury yield sat near 4.6% and markets saw roughly a 50 to 60% chance of a Federal Reserve rate hike in September. Rising oil prices kept inflation risks alive, putting energy producers and consumer-facing companies in focus. Among top movers, Nebius Group jumped 18.78% after Nvidia disclosed a 9.3% passive stake, Cerebras Systems surged 17.92%, and Bloom Energy climbed 14.82% after JPMorgan raised its price target. On the losing side, Boxabl declined 18.43%, Danaher fell 10.99% after issuing third-quarter revenue guidance of 2% to 3% growth, and MSCI dropped 10.14% after Morgan Stanley cut its price target to US$700 from US$727. Earnings from Alphabet, Tesla, Texas Instruments, AT&T, Verizon Communications, and American Express were set to dominate the next three sessions.
Dow Rebounds 385 Points as Chip Stocks Surge, Leading US Market Higher
US stocks closed higher on Tuesday, with the Dow rebounding 385.38 points to 52,224.64. The S&P 500 gained 0.89% and the Nasdaq jumped 1.29%, led by a strong recovery in semiconductor stocks. The Philadelphia SE Semiconductor Index, or SOX, surged 5.2% for a second straight day, after falling more than 20% from its record high in late June. Despite the recent heavy sell-off, the chip index is still up nearly 75% since the start of the year. Investors are watching earnings from major technology companies this week, especially Alphabet, Intel, and Texas Instruments, to gauge the outlook for the AI business. 3M shares jumped 7.3% after raising its full-year profit forecast, while Hasbro surged 8.8% on demand for digital games and Magic: The Gathering. Danaher fell 11% after cutting its revenue outlook, and MSCI dropped 10% after increasing its operating expense forecast.
Danaher Raises Full-Year EPS Guidance After Q2 Beat and Early Masimo Close
Danaher Corporation reported second-quarter 2026 revenue of $6.3 billion, with core revenue up 3% year-over-year, and raised its full-year adjusted diluted EPS guidance to a range of $8.45 to $8.60. Non-respiratory core growth accelerated to 4.5%, a 150-basis-point improvement from the first quarter, driven by recovery in life sciences and diagnostics end markets. Adjusted diluted EPS came in at $1.94, an 8% increase, while free cash flow reached $1.3 billion for the quarter. The company closed its acquisition of Masimo in early June, which delivered high single-digit revenue growth in the first half, and announced the pending acquisition of StatLab, a pathology consumables manufacturer with approximately $250 million in 2025 revenue. Bioprocessing orders grew mid-teens in both consumables and equipment, though approximately $100 million in chromatography resin revenue shifted from 2026 into 2027 due to customer site readiness and production schedule changes. Full-year core revenue guidance was maintained at 3% to 4%, with third-quarter revenue growth expected at 2% to 3%, including a 250-basis-point headwind from respiratory testing.
Stocks Gain as Chipmakers Rebound Ahead of Megacap Earnings
U.S. stock indexes climbed on Tuesday as a rebound in chipmakers and AI-infrastructure stocks gathered pace. The S&P 500 rose 0.38%, the Dow Jones Industrial Average added 0.17%, and the Nasdaq 100 jumped 1.26%. Chipmakers rallied after a recent selloff cheapened valuations, drawing dip buyers ahead of megacap technology earnings this week, starting with Alphabet on Wednesday. Software stocks were weak after Morgan Stanley downgraded several companies in the sector, including Adobe, Intuit, and Workday. Hasbro surged more than 10% after reporting better-than-expected quarterly revenue and raising its full-year adjusted Ebitda forecast, while 3M gained over 8% on stronger earnings and an improved outlook. Danaher fell more than 13% after issuing a weaker revenue growth forecast, and MSCI dropped over 10% on an earnings miss and higher expense guidance.
Danaher reported better-than-expected second-quarter results with sales of $6.3 billion, adjusted EPS of $1.94, and $1.3 billion in free cash flow. Core revenue rose 3% year over year, while the Life Sciences segment posted 5.5% core growth, its strongest quarter in several years. The company raised full-year 2026 adjusted EPS guidance to a range of $8.45 to $8.60, while keeping core revenue growth guidance at 3% to 4%. Management said bioprocessing shipment delays hurt the quarter, but underlying demand remained strong and life sciences strength is expected to offset some of that pressure.
Danaher beats Q2 revenue estimates but stock drops 9.8%
Danaher reported second-quarter 2026 revenue of $6.27 billion, exceeding analyst expectations of $6.1 billion and marking a 5.5% year-on-year increase. Adjusted earnings per share came in at $1.94, a 4.9% beat over the consensus estimate of $1.85. Management slightly raised its full-year adjusted EPS guidance to $8.52 at the midpoint. Despite the beats, the stock fell 9.8% to $181.82 immediately after the results, suggesting the market was hoping for more.
High-throughput Screening Market to Reach USD 45.90 Billion by 2031
The global high-throughput screening market is projected to grow from USD 27.66 billion in 2026 to USD 45.90 billion by 2031, at a compound annual growth rate of 10.7 percent, according to a new report from MarketsandMarkets. Growth is driven by rising pharmaceutical and biotechnology R&D investments, increasing adoption of automated drug discovery platforms, and technological advances in areas such as cell-based screening and artificial intelligence-enabled analytics. The products segment accounted for the largest share of the market in 2025, with reagents, kits and consumables being the largest product type due to their recurring use across screening workflows. Asia Pacific is expected to register the highest growth rate during the forecast period, supported by expanding research activities and growing contract research organization presence in countries including China, India, Japan, and South Korea. Key players in the market include Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, Danaher Corporation, and Revvity, with the top participants collectively holding approximately 38 percent of the global market.
Today's Economic Schedule: White Goods Shipments, Overseas Earnings, and More
Today in Japan, June white goods shipment figures, supermarket food sales, major convenience store sales, and Tokyo metropolitan area condominium market trends are scheduled for release. Overseas, the UK June unemployment rate, and Germany and the Eurozone July ZEW economic sentiment indices will be announced. On the earnings front, Charles Schwab, Danaher, Capital One Financial, 3M, and General Motors are set to report. Additionally, Magmag will dual-list on the Fukuoka Stock Exchange Q-Board.
Zacks highlights research reports on Interactive Brokers, Danaher, and S&P Global
Zacks Investment Research released new research reports on 16 major stocks, including Interactive Brokers, Danaher, and S&P Global, as well as a micro-cap stock Optical Cable. Interactive Brokers has outperformed its industry over the past year with a 64.7% gain versus 33.2%, driven by a widening product set and automated platform, though earnings remain sensitive to benchmark-rate changes and elevated expenses. Danaher's shares gained 3.9% over the past year, lagging the Zacks Medical Services industry's 18% gain, with strength in bioprocessing and filtration offset by weakness in diagnostics and high debt. S&P Global's shares declined 10.5% over the past year, slightly better than its industry's 11.4% decline, as subscription-based revenue and the IHS Markit acquisition support growth amid rising expenses and competitive pressures. Optical Cable, a micro-cap with a market capitalization of $144.85 million, saw its shares rise 175.8% over the past year, in line with the Zacks Fiber Optics industry, supported by demand from enterprise, data center, and severe-duty markets, though risks include constrained liquidity and customer concentration.
Danaher Set to Report Q2 Earnings With Positive Surprise Signal
Danaher Corporation is scheduled to release second-quarter 2026 results on July 21 before market open, with the Zacks Consensus Estimate for revenues pegged at $6.09 billion and earnings at $1.84 per share. The earnings estimate has risen a penny in the past seven days and implies a 2.2% increase from the year-ago quarter, while the revenue estimate indicates a 2.6% rise. The company's bottom line surpassed the consensus in each of the preceding four quarters, delivering an average beat of 6.7%. Zacks' model predicts another beat this time, as Danaher carries an Earnings ESP of +0.62% and a Zacks Rank of 2. Key drivers include strength in the bioprocessing business within the Biotechnology segment, where the consensus sales estimate is $1.95 billion, and the June 2026 acquisition of Masimo Corp. for $9.9 billion, which is expected to have enhanced the diagnostics portfolio. However, escalating costs and higher interest expenses may have weighed on profitability.
Life Science Tools Market Projected to Reach USD 503.69 Billion by 2035
The global life science tools market is projected to grow from USD 175.96 billion in 2025 to USD 503.69 billion by 2035, at a compound annual growth rate of 11.09%, according to a new report by SNS Insider. North America led the market in 2025, with the U.S. segment valued at USD 68.50 billion and forecast to reach USD 189.48 billion by 2035, while the Asia-Pacific region is expected to record the fastest growth at a CAGR of more than 12%. Next-generation sequencing held the largest technology share at over 30% in 2025 and is also the fastest-growing technology segment, driven by applications in single-cell sequencing, liquid biopsy, and rare diseases. Instruments accounted for more than 52% of the market by type, and biopharmaceutical companies represented the largest end-user segment with an estimated 44% share. Key players include Agilent Technologies, Illumina, Thermo Fisher Scientific, and Danaher, with recent developments such as Agilent's expansion of its genomics portfolio in 2025 and Illumina's enhanced sequencing platforms in 2024.
Global Laboratory Centrifuges Market to Reach USD 1.86 Billion by 2030
The global laboratory centrifuges market is projected to grow from USD 1.58 billion in 2025 to USD 1.86 billion by 2030, at a compound annual growth rate of 2.8%. Equipment held the largest product segment share in 2025, driven by technology upgrades and replacement cycles. Benchtop centrifuges led the platform segment due to their affordability and compact footprint, while hospitals remained the largest end-user segment because of high diagnostic testing volumes. Asia Pacific is expected to register the highest regional growth rate, fueled by healthcare infrastructure investments in China and India. Key players include Thermo Fisher Scientific, Danaher, and Eppendorf.
Jim Cramer tells investors to stay away from Danaher
Jim Cramer advised investors to avoid Danaher Corporation, calling the stock a huge disappointment during a recent Mad Money episode. Responding to a caller, Cramer said he does not want anyone near Danaher, though he acknowledged it could go higher and has a good chart. He noted the company trades at 21 times earnings but is only posting 4 to 6% organic growth, making it overvalued at current prices. Cramer contrasted Danaher with Thermo Fisher, which trades at less than 20 times earnings but has a 1% organic growth rate.
South Korea automated liquid handling system market to reach $51 million by 2036
The South Korea automated liquid handling system market is projected to grow from $23.5 million in 2025 to $51.0 million by 2036, at a compound annual growth rate of 7.47%. The automated liquid handling system segment is expected to dominate by type, while liquid handling workstations lead by product. Drug discovery is the leading application, and pharmaceutical and biotechnology companies are the primary end users. Key players include Agilent Technologies, Revvity, Thermo Fisher Scientific, Danaher, and Tecan Group.
Danaher's Beckman Coulter wins CE Mark for Access p-Tau217 blood assay
Beckman Coulter Diagnostics, part of Danaher, has received CE Mark under IVDR for its Access p-Tau217 blood assay. The regulatory milestone arrives as Danaher's stock trades at $190.77, down 17.2% year to date, with a one-year total shareholder return of negative 4.37%. Analyst targets and one intrinsic value estimate place fair value roughly 26% higher, while a popular narrative pegs fair value at $242.35, suggesting the stock is undervalued. A discounted cash flow model estimates fair value at $259.47, though pressure on biotech and academic spending, along with China policy changes affecting diagnostics revenue, could challenge the bullish case.
StockStory highlights McDonald's as cash-producing stock with competitive advantages, flags Hyatt and Danaher as less attractive
StockStory identifies McDonald's as a cash-producing stock with competitive advantages, while suggesting Hyatt Hotels and Danaher may face challenges. McDonald's trailing 12-month free cash flow margin stands at 25.6%, supported by a highly profitable franchise model and a gross margin of 57.1%. Hyatt Hotels reported a free cash flow margin of just 1.6% and annual sales growth of 3.2% over two years, below typical consumer discretionary companies. Danaher's free cash flow margin is 21.4%, but its organic revenue has disappointed and operating margin fell by 7 percentage points over five years.
Danaher Biotechnology Segment Core Revenues Rise 7% in Q1 2026
Danaher Corporation's Biotechnology segment core revenues increased 7% year over year in the first quarter of 2026, driven by strength in the bioprocessing business and higher sales in Western Europe and China. Bioprocessing orders for equipment rose more than 30%, and the company expects core revenues from bioprocessing to grow in high single digits for the full year. Despite headwinds from weak demand for medical filtration and research consumables, Danaher anticipates mid-single-digit core revenue growth for the Biotechnology segment in the second quarter. The company's shares have gained 3% in the past month, and it carries a Zacks Rank of 2, or Buy.
Exosome Diagnostics Market to Reach USD 815 Million by 2031
The global exosome diagnostics market is projected to reach USD 815.0 million by 2031, growing at a compound annual growth rate of 11.8% from USD 466.2 million in 2026. Growth is driven by rising demand for minimally invasive diagnostics, advancements in biomarker discovery, and increasing adoption of liquid biopsy technologies, particularly in oncology. North America leads the market due to advanced healthcare infrastructure, while Asia-Pacific is expected to see rapid expansion fueled by investments in countries like China and India. Key players include Danaher Corporation, Thermo Fisher Scientific, and Exosome Diagnostics Inc., with competition centered on product innovation and strategic partnerships. Challenges include standardization of exosome isolation and regulatory uncertainty.
Danaher Completes $9.9B Acquisition of Masimo Corporation
Danaher has completed its $9.9 billion acquisition of Masimo Corporation, a specialist in pulse oximetry and patient monitoring solutions. Masimo will now operate as a standalone company within Danaher's Diagnostics segment, retaining its brand identity as a wholly owned subsidiary, and its common stock has been delisted from the NASDAQ. Danaher views the deal as a strategic move to enhance its diagnostics portfolio in acute care settings through Masimo's sensor and AI-monitoring technologies, expecting it to accelerate Masimo's global reach. The company's current 2026 guidance remains unchanged for the second quarter, as Masimo is not expected to contribute materially until later in the year, with updated full-year 2026 financial guidance to be provided during the second-quarter earnings release.
Danaher shares rise after Masimo unit gets FDA clearance for AI-powered opioid detection feature
Danaher shares rose 2.8% in morning trading after its recently acquired subsidiary Masimo received FDA clearance for an artificial intelligence-enabled feature on its wearable patient monitoring platform. The approved feature is designed to detect opioid-induced respiratory depression. Danaher officially acquired Masimo in June 2026, expanding its footprint in specialty diagnostics and patient-monitoring technologies. The shares were trading at $194.71, up 3.1% from the previous close.
Three Healthcare Stocks with Questionable Fundamentals
Three healthcare stocks may face trouble due to weak fundamentals. Danaher has seen no organic revenue growth over the past two years, its operating margin fell by 10.6 percentage points over five years, and earnings per share were flat. Solventum's organic revenue growth fell short of benchmarks, sales are projected to be flat over the next 12 months, and its free cash flow margin dropped by 30.8 percentage points over five years. agilon health experienced underwhelming customer growth, flat revenue is expected over the next 12 months, and the company has cash-burning tendencies.
Masimo, a Danaher company, receives FDA clearance for AI-enabled opioid-induced respiratory depression detection feature
Masimo, a Danaher company, received FDA 510(k) clearance for an AI-enabled opioid-induced respiratory depression detection feature integrated into its Radius VSM wearable continuous patient monitor. The clearance, announced on 22 June 2026, highlights Danaher's push to advance pulse oximetry beyond basic vital sign tracking toward AI-driven, clinically actionable insights in hospital monitoring. While the new feature aligns with Danaher's strategy of compounding recurring consumables and services revenue while upgrading its technology base, it is unlikely on its own to shift near-term catalysts tied to broader healthcare demand or risks from China policy changes and biopharma funding softness. Investors may look to the upcoming Q2 2026 earnings call on 21 July for management's framing of Masimo's AI-driven monitoring within Danaher's wider innovation and margin ambitions.
Danaher Stock Falls 22% This Year After Masimo Acquisition
Danaher's stock has dropped more than 22% this year, largely due to its $9.9 billion acquisition of Masimo, which expands the company beyond life sciences consumables into clinical patient monitoring. The deal raised concerns about a patent dispute with Apple and added significant debt. Danaher reported first-quarter revenue of $5.95 billion, up 3% year over year, and earnings per share of $1.45, up 9.8%. The company expects the Masimo acquisition to add $0.15 to $0.20 to adjusted diluted EPS in the first full year, scaling to $0.70 by year five, and raised its 2026 adjusted EPS guidance to a range of $8.35 to $8.55. The stock now trades at just over 20 times forward earnings, well below its typical decade-long valuation, though integration risks and the Apple patent fight remain concerns.